Skip to main content

About Us

Plexision develops cellular biomarkers for personalized diagnostics and drug development in infectious diseases, solid organ transplantation, as well as immuno-oncology. These tests are based on patented technology that measures antigen-specific white blood cells.

Testing services for patients, researchers, and drug developers are provided by Plexision’s CLIA-certified, GMP-compliant central laboratory in Pittsburgh, Pennsylvania.

Plexision’s team consists of highly-trained technologists, cytometrists, clinicians, scientists, bioentrepreneurs, and bioinformaticians.

Plexision currently offers a wide array of lab-developed cell-based diagnostic tests for personalized patient care. The patented technology underlying these testing systems has been used to support custom R&D projects in both the industry and academia.

Plexision’s first product, the FDA-approved PleximmuneTM blood test predicts transplant rejection. PlexCOVID-19, the most recent blood test, measures the risk and severity of COVID-19 infection.

Our technology can be adapted to -

  • Assess disease risk for several immunological disorders.
  • Predict the success of a drug for a specific patient.
  • Develop dosing recommendations for new immunological drugs.

 

Rajeev Sindhi

Rajeev Sindhi has been in the healthcare business for the last 20 years. He is the Co-founder of Plexision, Chief Executive Officer, and a Chairman on Plexision’s Board of Directors. Sindhi is also the Managing Director of the Sandor group in India. The Sandor group is a distribution partner for multinationals such as Sanofi, Abbott, and Cantel; they provide diagnostic and scientific services in genetics and genomics in India. The flagship company of the group, Sandor Medicaids Pvt. Ltd serves more than 2,500 hospitals in India and Southeast Asia. 

Rakesh Sindhi

Rakesh Sindhi, M.D., is a transplant surgeon, Co-founder of Plexision, Chief Scientific Officer, and a member of Plexision’s Board of Directors. He is also a Professor of Surgery, Co-Director of Pediatric Transplant Surgery, and Director of Pediatric Transplant Research at the University of Pittsburgh; where he developed all technology underlying Plexision's products. This technology is exclusively licensed to Plexision by the University. Sindhi has authored 15 patent applications along with being the author or co-author of over 130 peer-reviewed papers. He has received several grants from the National Institute of Health allowing him to study the immunogenetic basis of transplant rejection and the genetic basis of biliary atresia, the leading congenital cause of liver transplantation in children.

Ashok Reddy

Ashok Reddy is the Director of Operations and has been with Plexision since 2008. He has worked for over three decades in senior management positions, specializing in all aspects of operations. This experience includes personnel management, contract and labor negotiations, client relationships, operational analysis, budgeting, process re-engineering, and workflow optimization. In the last two decades, Reddy has also held operational roles in the information technology and healthcare IT space. He previously worked as the Senior Vice-President of Operations at Infinite Computer Solutions for over a decade before co-founding IQGateway, a predictive analytics company, where he served as the Chief Operating Officer. Reddy also serves as a consultant to Infinite Healthcare Solutions, a company focused on helping veterans.

Rajeev Sindhi

Rajeev Sindhi has been in the healthcare business for the last 20 years. He is the Co-founder of Plexision, Chief Executive Officer, and a Chairman on Plexision’s Board of Directors. Sindhi is also the Managing Director of the Sandor group in India. The Sandor group is a distribution partner for multinationals such as Sanofi, Abbott, and Cantel; they provide diagnostic and scientific services in genetics and genomics in India. The flagship company of the group, Sandor Medicaids Pvt. Ltd serves more than 2,500 hospitals in India and Southeast Asia. 

Rakesh Sindhi

Rakesh Sindhi, M.D., is a transplant surgeon, Co-founder of Plexision, Chief Scientific Officer, and a member of Plexision’s Board of Directors. He is also a Professor of Surgery, Co-Director of Pediatric Transplant Surgery, and Director of Pediatric Transplant Research at the University of Pittsburgh; where he developed all technology underlying Plexision's products. This technology is exclusively licensed to Plexision by the University. Sindhi has authored 15 patent applications along with being the author or co-author of over 130 peer-reviewed papers. He has received several grants from the National Institute of Health allowing him to study the immunogenetic basis of transplant rejection and the genetic basis of biliary atresia, the leading congenital cause of liver transplantation in children.

Brandon W. Higgs

Brandon W. Higgs, Ph.D., is the Bioinformatics Group Lead within Translational Sciences at MedImmune, focusing on biomarker discovery and advancement to enhance drug development. Prior to this, he was a Senior Scientist at MITRE, a federally funded R&D company working for the Department of Defense, where he lead epidemiological integration for the CDC. Higgs also developed detection approaches for biothreats and syndromic surveillance. Previously, he worked as a Biostatistician at Gene Logic, where he developed predictive models of toxicity. He is adjunct faculty in the Bioinformatics Graduate Program at Johns Hopkins University and received his Ph.D. in Bioinformatics and Computational Biology from George Mason University. Higgs also holds an M.S in Bioinformatics from Johns Hopkins University as wells as a B.S in Biochemistry from Indiana University.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact